We conducted this meta-analysis to examine the association between Helicobacter pylori and esophageal adenocarcinoma (EAC) and esophageal squamous cell carcinoma. We searched the PubMed database, the ISI database, and the references of the selected articles. Case-control or nested case-control studies were selected if they used serology or endoscopic methods to detect H. pylori in the stomach and if control subjects were not restricted to upper gastrointestinal tract cancer or peptic ulcer disease patients. A total of 19 studies were used for this analysis. Summary odds ratios (OR) and 95% confidence intervals (95% CI) were calculated using the DerSimonian-Laird method. Q statistics and I2 statistics were calculated to examine heterogeneity. Subgroup analyses were conducted by CagA status. For EAC, the summary OR (95% CI) was 0.56 (0.46-0.68). There was little heterogeneity among studies (I2 = 15%). Further analysis showed that colonization with CagA-positive strains was inversely associated with EAC risk (OR, 0.41; 95% CI, 0.28-0.62) but colonization with CagA-negative strains was not (OR, 1.08; 95% CI, 0.76-1.53). For esophageal squamous cell carcinoma, the summary OR (95% CI) was 1.10 (0.78-1.55). However, there was substantial heterogeneity among studies (I2 = 73%), with statistically significant associations in both directions. Our results suggest an inverse association between CagA-positive H. pylori colonization and risk of EAC. The prominent decline of H. pylori colonization in the past few decades may be partly responsible for the recent increase in EAC incidence in Western countries.

Since its discovery in the early 1980s (1), Helicobacter pylori has been associated with several benign and malignant gastrointestinal tract diseases. H. pylori is now a known cause of gastric and duodenal ulcers, noncardia gastric adenocarcinoma, and gastric MALT lymphoma (2). In addition, epidemiologic studies have investigated the association between H. pylori and other gastrointestinal malignancies, including pancreatic cancer (3, 4), colorectal cancer (5, 6), and esophageal cancer. Of these, the association with esophageal cancer has been examined in a larger number of studies and relatively consistent patterns of association are emerging. Systematic reviews will help in establishing such patterns.

With over 450,000 new cases annually, esophageal cancer is the 8th most common incident cancer in the world (7). The two main histologic types of esophageal cancer, esophageal squamous cell carcinoma (ESCC) and esophageal adenocarcinoma (EAC), have distinct geographic and demographic patterns. ESCC constitutes the large majority of all esophageal cancer cases in the world (7, 8) and more than 90% of the cases in some high-risk areas of the world, such as China (9) and Iran (10). EAC constitutes the minority of esophageal cancer cases in the world, but approximately half of the cases in some Western countries, such as the United States and the United Kingdom, are of this type (1113). There is also a large body of evidence suggesting that the risk factors for these two cancer types may be different. For example, alcohol consumption is a strong risk factor for ESCC but its association with EAC is unclear (14, 15). Therefore, the associations of any potential causal factors should be evaluated separately for these two cancer types.

H. pylori resides in the stomach and can be detected with a number of invasive methods, such as histologic examination or urease test on gastric antral biopsies, or by noninvasive methods, such as serologic tests (16). Of these, positive serologic tests indicate past or current colonization, whereas other methods indicate only current colonization of H. pylori in the stomach. Because of the low cost, the ability to detect previous exposure, and the availability of serum in epidemiologic studies, serologic tests are especially useful in such studies.

There are different strains of H. pylori. The genome of CagA-positive strains contains the cag pathogenicity island. This island includes approximately 31 putative genes, including cagA—the gene that encodes the CagA protein (17). CagA-positive strains confer a higher risk of noncardia gastric cancer than CagA-negative strains (18). Likewise, the association between CagA-positive and CagA-negative strains with other cancers may be different (19) and should be considered in analyses.

We conducted this meta-analysis to summarize the published literature on the association between H. pylori, detected by different methods, and esophageal cancer. We analyzed and report the results separately for ESCC and EAC. We also report the associations by CagA status.

Selection of studies

We conducted a comprehensive search by examining the PubMed and ISI-Web of Knowledge databases for all case-control or cohort studies that have been published on the association between H. pylori colonization in the stomach and risk of esophageal cancer. All results were updated on February 12, 2008. The following terms were used in the PubMed Database search: [“Helicobacter pylori” [MeSH] OR (Campylobacter pylori) OR (H Pylori) OR (H. Pylori)] AND [“Esophageal Neoplasms” [MeSH] OR (Cancer of Esophagus) OR (Cancer of the Esophagus) OR (Esophageal Cancer) OR (Esophagus Cancer) OR (Esophagus Neoplasm) OR (Neoplasms, Esophageal)]. The same terms were used to search text words in the ISI Database. The search was repeated by replacing Esophagus with Oesophagus, and Esophageal with Oesophageal. In addition, references cited in the identified articles were searched manually. Both authors reviewed the search results to reduce the possibility of missing the published articles. Where data were missing, we contacted the authors for the relevant information. Using these approaches, reports on H. pylori in relation to esophageal cancer were found in 35 full-text articles (1953).

Inclusion criteria were (a) testing for the presence of H. pylori in the stomach using invasive or noninvasive methods and (b) including control subjects without upper gastrointestinal cancers or peptic ulcer disease. Based on these criteria, three studies were excluded because they examined the presence of H. pylori only in esophageal tissue samples (but not in the stomach; refs. 30, 43, 49). Six studies were excluded because they had no control subjects or because all control subjects had upper gastrointestinal tract cancers or peptic ulcers (22, 26, 34, 3739). Six more studies (19, 24, 32, 40, 44, 51) were excluded because the H. pylori assay results were also reported in other publications (23, 27, 36, 41, 50, 53). Finally, one study was excluded because cancers of the proximal 5 cm of stomach were considered as esophageal cancer (29). Therefore, a total of 19 studies were used for calculating summary statistics.

Data extraction and statistical analysis

We compared H. pylori positivity in esophageal cancer cases and controls. H. pylori positivity was defined as having evidence for H. pylori colonization by direct (invasive) examination of the gastric antral tissue or being seropositive for IgG antibodies against whole-cell antigen. In an additional analysis, we used a broader definition of H. pylori positivity, defined as having evidence for H. pylori colonization by direct examination of the gastric antral tissue, being seropositive for IgG antibodies against H. pylori whole-cell antigen, or being seropositive for IgG antibodies against CagA. We chose this broader definition because individuals who are seronegative for antibodies against whole-cell antigen but are seropositive for antibodies against CagA may in fact be positive for H. pylori (54). Where data were available, we compared the presence of CagA-positive strains (versus no H. pylori), and the presence of CagA-negative strains (versus no H. pylori) between case and control subjects. In all studies, CagA positivity was determined using IgG antibodies.

We calculated odds ratios (OR) and 95% confidence intervals (95% CI) for the association between each of the exposures noted above and esophageal cancer. ORs and 95% CIs were calculated for each individual study and for all studies combined. We used both random-effects models (DerSimonian-Laird method) and fixed-effects models (Mantel-Haenszel method) to calculate summary ORs and 95% CIs. Because these two methods provided qualitatively similar results, we chose random-effects models, which are more conservative than fixed-effects models (55), to present forest plots and subgroup analyses described in the text.

We conducted several subgroup analyses. In a number of studies, the control subjects were selected from among clinic patients who were endoscoped because of upper gastrointestinal tract symptoms. Use of such control subjects may bias results because the H. pylori colonization rate in such control subjects may be different from the rate in the general population. Therefore, subgroup analyses were done that included only population-based studies. We also did subgroup analyses for studies from Western (European and American) and Eastern (Asian) countries, which may have different H. pylori positivity rates in their general populations. High prevalence of H. pylori colonization among controls may conceal an association between H. pylori and disease, especially if the association is not very strong. Only serologic studies are able to detect past exposure to H. pylori. Therefore, we also calculated summary ORs (95% CIs) for the subgroup of studies that had used serologic tests. H. pylori colonization rate is usually higher in older subjects, mostly because of cohort effects. Therefore, subgroup analyses were done for studies that had used age-matched controls (group-matched or individual-matched). Differentiating between EAC and gastric cardia adenocarcinoma can be challenging. To differentiate between the two, some studies required the presence of Barrett's esophagus for diagnosis of EAC. We conducted a subgroup analysis using these studies. Because the association between H. pylori and esophageal cancer could potentially be confounded by other factors, e.g., socioeconomic status, we also calculated and present the summary of adjusted ORs (95% CIs) for studies that provided adjusted results.

We plotted Begg's funnel plot to examine small study effects (56). We also used Begg and Mazumdar's method (57) to calculate P for rank correlation and Egger's weighted regression method (58) to calculate P for bias. For sensitivity analysis, we excluded smaller studies and recalculated the summary ORs (95% CIs) using only larger studies.

To examine heterogeneity among studies, the Q statistic (using Mantel-Haenszel weights) and the I2 statistic (59) were calculated. All analyses were done using STATA software, version 10.0 (StataCorp LP). Throughout the article, two-sided P values <0.05 were considered as statistically significant.

Summary characteristics of the 19 studies that were included in this analysis are presented in Table 1. Most studies used serologic tests to determine prior or current stomach colonization with H. pylori and to determine CagA status. Approximately half of the studies were population based, whereas the other half were clinic based.

Table 1

Study characteristics

First authorStudy locationYear*Study typeHP DxHP+ definitionEACESCCMatched/adjusted§Controls
CaseControlCaseControl
HP+CagA+HP+CagA+HP+CagA+HP+CagA+
1. Talley (42) USA 1991 Clin HPSe+ — — — — 20/41 — 96/252 — No/yes Asymptomatic volunteers and patients with benign esophageal, lung, or musculoskeletal disorders 
2. Oberg (35) USA 1999 Clin Hist+ 5/37 — 32/229 — — — — — No/no Patients with foregut symptoms and benign diseases 
3. Peek (36) USA 1999 Clin S, H HPSe+ or Hist+ 11/30 3/30 20/48 25/48 — — — — No/no Patients endoscoped for reasons other than GERD or Barrett's 
4. Vieth (45) Germany 2000 Clin Hist+ 66/138 — 468/712 — — — — — No/no Patients with non–ulcer dyspepsia and no endoscopic signs of GERD 
5. Weston (48) USA 2000 Clin Hist+ 3/20 — 96/217 — — — — — No/no Patients with GERD symptoms but no Barrett's esophagus 
6. El Omar (27) USA 2003 Pop HPSe+ 35/108 5/68 84/210 46/224 31/53 7/26 84/210 46/224 Yes/no Matched to cases for age, sex, and study center 
7. Wu AH (50) USA 2003 Pop HPSe+ (HPSe+ or CagA+) 49/80 (52/80) 18/80 230/356 (249/356) 106/356 — — — — Yes/yes Matched to cases for age, sex, neighborhood of residence, and race 
8. Wang KX (46) China 2003 NR HPSe+ — — — — 33/63 — 145/310 — NR/no Healthy subjects 
9. Ye (53) Sweden 2004 Pop HPSe+ (HPSe+ or CagA+) 18/97 (47/97) 42/97 198/499 (304/499) 293/499 32/85 (64/85) 63/85 198/499 (304/499) 293/499 Yes/yes Randomly selected population-based controls, frequency matched to EAC cases for age and sex 
10. de Martel (23) USA 2005 Pop HPSe+ 19/51 9/18 74/150 44/71 — — — — Yes/yes Randomly selected from the study cohort, matched to cases for age, sex, race, and study site 
11. Wu DC (52) Taiwan 2005 Pop HPSe+ — — — — 28/127 — 74/171 — No/yes Parents of children randomly selected from the study area 
12. Wang Z (47)** China 2006 Pop HPSe+ — — — — ?/107 — ?/107 — Yes/yes Neighborhood controls, randomly selected and matched to cases for age and sex 
13. Siman (41) Sweden 2007 Pop HPSe+ (HPSe+ or CagA+) 4/12 (7/12) 6/12 24/47 (35/47) 32/47 15/37 (24/37) 24/37 68/129 (87/129) 82/129 Yes/yes Randomly selected from the study cohort, matched to cases for age, sex, and date of enrollment 
14. Kamangar (33) China 2007 Pop HPSe+ (HPSe+ or CagA+) — — — — 231/335 (254/335) 178/335 662/992 (727/992) 552/992 No/yes Randomly selected from the baseline participants in the study cohort 
15. Anandasabapathy (20) USA 2007 Clin Hist+ 4/25 — 10/30 — — — — — No/no Barrett's patients with no dysplasia 
16. Iijima (31) Japan 2007 Clin S, H,U HPSe+, Hist+, or U+ — — — — 60/73 56/73 — Yes/yes Endoscoped patients with no localized lesion, matched to cases for age and sex 
17. Derakhshan (25) Iran 2008 Clin HPSe+ 9/19 — 28/38 — — — — — Yes/yes Dyspeptic patients with no peptic ulcer or tumor in their endoscopy 
18. Fruh (28) USA 2008 Clin HPSe+ 36/100 29/100 43/101 30/101 — — — — Yes/yes Healthy GERD-free, non–blood-related family members and friends of other cancer/surgical patients 
19. Anderson (21) Ireland 2008 Pop HPSe+ 55/123 57/123 157/253 150/253 — — — — Yes/yes Randomly selected population-based controls, frequency matched to EAC cases for age and sex 
First authorStudy locationYear*Study typeHP DxHP+ definitionEACESCCMatched/adjusted§Controls
CaseControlCaseControl
HP+CagA+HP+CagA+HP+CagA+HP+CagA+
1. Talley (42) USA 1991 Clin HPSe+ — — — — 20/41 — 96/252 — No/yes Asymptomatic volunteers and patients with benign esophageal, lung, or musculoskeletal disorders 
2. Oberg (35) USA 1999 Clin Hist+ 5/37 — 32/229 — — — — — No/no Patients with foregut symptoms and benign diseases 
3. Peek (36) USA 1999 Clin S, H HPSe+ or Hist+ 11/30 3/30 20/48 25/48 — — — — No/no Patients endoscoped for reasons other than GERD or Barrett's 
4. Vieth (45) Germany 2000 Clin Hist+ 66/138 — 468/712 — — — — — No/no Patients with non–ulcer dyspepsia and no endoscopic signs of GERD 
5. Weston (48) USA 2000 Clin Hist+ 3/20 — 96/217 — — — — — No/no Patients with GERD symptoms but no Barrett's esophagus 
6. El Omar (27) USA 2003 Pop HPSe+ 35/108 5/68 84/210 46/224 31/53 7/26 84/210 46/224 Yes/no Matched to cases for age, sex, and study center 
7. Wu AH (50) USA 2003 Pop HPSe+ (HPSe+ or CagA+) 49/80 (52/80) 18/80 230/356 (249/356) 106/356 — — — — Yes/yes Matched to cases for age, sex, neighborhood of residence, and race 
8. Wang KX (46) China 2003 NR HPSe+ — — — — 33/63 — 145/310 — NR/no Healthy subjects 
9. Ye (53) Sweden 2004 Pop HPSe+ (HPSe+ or CagA+) 18/97 (47/97) 42/97 198/499 (304/499) 293/499 32/85 (64/85) 63/85 198/499 (304/499) 293/499 Yes/yes Randomly selected population-based controls, frequency matched to EAC cases for age and sex 
10. de Martel (23) USA 2005 Pop HPSe+ 19/51 9/18 74/150 44/71 — — — — Yes/yes Randomly selected from the study cohort, matched to cases for age, sex, race, and study site 
11. Wu DC (52) Taiwan 2005 Pop HPSe+ — — — — 28/127 — 74/171 — No/yes Parents of children randomly selected from the study area 
12. Wang Z (47)** China 2006 Pop HPSe+ — — — — ?/107 — ?/107 — Yes/yes Neighborhood controls, randomly selected and matched to cases for age and sex 
13. Siman (41) Sweden 2007 Pop HPSe+ (HPSe+ or CagA+) 4/12 (7/12) 6/12 24/47 (35/47) 32/47 15/37 (24/37) 24/37 68/129 (87/129) 82/129 Yes/yes Randomly selected from the study cohort, matched to cases for age, sex, and date of enrollment 
14. Kamangar (33) China 2007 Pop HPSe+ (HPSe+ or CagA+) — — — — 231/335 (254/335) 178/335 662/992 (727/992) 552/992 No/yes Randomly selected from the baseline participants in the study cohort 
15. Anandasabapathy (20) USA 2007 Clin Hist+ 4/25 — 10/30 — — — — — No/no Barrett's patients with no dysplasia 
16. Iijima (31) Japan 2007 Clin S, H,U HPSe+, Hist+, or U+ — — — — 60/73 56/73 — Yes/yes Endoscoped patients with no localized lesion, matched to cases for age and sex 
17. Derakhshan (25) Iran 2008 Clin HPSe+ 9/19 — 28/38 — — — — — Yes/yes Dyspeptic patients with no peptic ulcer or tumor in their endoscopy 
18. Fruh (28) USA 2008 Clin HPSe+ 36/100 29/100 43/101 30/101 — — — — Yes/yes Healthy GERD-free, non–blood-related family members and friends of other cancer/surgical patients 
19. Anderson (21) Ireland 2008 Pop HPSe+ 55/123 57/123 157/253 150/253 — — — — Yes/yes Randomly selected population-based controls, frequency matched to EAC cases for age and sex 

Abbreviations: Clin, clinic based; Pop, population based; NR, not reported; HP Dx, HP detection method; S, serology; H, histology; U, rapid urease test.

*Publication year.

Definition for H. pylori positivity: Hist+, positive histologic examination of tissue samples; HPSe+, seropositivity for antibodies to whole cell; CagA+, sero-positivity for antibodies to CagA; U+, positive rapid urease test.

Number of subjects with a positive test/total number of subjects.

§Group- or individual-matching of controls to cases for age/reporting adjusted ORs for the association between H. pylori or CagA and cancer.

EAC cases include Barrett's with high-grade dysplasia.

Because the authors reported that there was no difference in age and gender between cases and controls, this study was analyzed as a matched study.

**H pylori–positive numbers by case status were not reported.

Esophageal adenocarcinoma

Figure 1A and Table 2 show the results for the association between H. pylori and EAC. A total of 13 studies with 840 cases and 2,890 controls were included in this analysis. The OR point estimate for each individual study was below 1 (Fig. 1A), and the overall random effects and fixed effects ORs (95% CIs) were 0.56 (0.46-0.68) and 0.55 (0.47-0.66), respectively. For the overall association, the I2 statistic was 15%, suggesting little heterogeneity, and the P value associated with the Q statistic was 0.29, showing no statistically significant heterogeneity (Table 2).

Fig. 1

Forest plot and Begg's funnel for the association between H. pylori and esophageal cancer. Studies are sorted in order of publication year. A, esophageal adenocarcinoma. B, esophageal squamous cell carcinoma.

Fig. 1

Forest plot and Begg's funnel for the association between H. pylori and esophageal cancer. Studies are sorted in order of publication year. A, esophageal adenocarcinoma. B, esophageal squamous cell carcinoma.

Close modal
Table 2

Summary statistics for the association between H. pylori and esophageal adenocarcinoma

No. studiesQ statistic*PI2 (%)Random effects OR (95% CI)Fixed effects OR (95% CI)
H. pylori (840/2,890)§       
 All studies 13 14.19 0.29 15 0.56 (0.46–0.68) 0.55 (0.47–0.66) 
 Large studies (SE < 0.5) 9.64 0.21 27 0.58 (0.47–0.73) 0.57 (0.48–0.68) 
 Population-based studies 7.32 0.20 32 0.58 (0.43–0.76) 0.57 (0.46–0.71) 
 Western studies 12 13.28 0.28 17 0.57 (0.47–0.70) 0.56 (0.47–0.67) 
 Eastern studies — — 0.32 (0.10–1.02) 0.32 (0.10–1.02) 
 Studies used serologic tests 10 10.03 0.35 10 0.59 (0.48–0.73) 0.56 (0.47–0.67) 
 Studies with age-matched controls 9.17 0.24 24 0.58 (0.46–0.75) 0.58 (0.47–0.71) 
 Studies that required Barrett's  esophagus for EAC diagnosis 3.77 0.44 0.44 (0.33–0.58) 0.43 (0.33–0.56) 
 Adjusted results 13.25 0.04 55 0.50 (0.34–0.74) 0.52 (0.41–0.66) 
H. pylori (the broader definition) 13 16.60 0.17 28 0.56 (0.45–0.69) 0.57 (0.46–0.71) 
CagA-negative strains 1.64 0.80 1.08 (0.76–1.53) 1.07 (0.75–1.52) 
CagA-positive strains** 4.78 0.31 16 0.41 (0.28–0.62) 0.40 (0.28–0.56) 
No. studiesQ statistic*PI2 (%)Random effects OR (95% CI)Fixed effects OR (95% CI)
H. pylori (840/2,890)§       
 All studies 13 14.19 0.29 15 0.56 (0.46–0.68) 0.55 (0.47–0.66) 
 Large studies (SE < 0.5) 9.64 0.21 27 0.58 (0.47–0.73) 0.57 (0.48–0.68) 
 Population-based studies 7.32 0.20 32 0.58 (0.43–0.76) 0.57 (0.46–0.71) 
 Western studies 12 13.28 0.28 17 0.57 (0.47–0.70) 0.56 (0.47–0.67) 
 Eastern studies — — 0.32 (0.10–1.02) 0.32 (0.10–1.02) 
 Studies used serologic tests 10 10.03 0.35 10 0.59 (0.48–0.73) 0.56 (0.47–0.67) 
 Studies with age-matched controls 9.17 0.24 24 0.58 (0.46–0.75) 0.58 (0.47–0.71) 
 Studies that required Barrett's  esophagus for EAC diagnosis 3.77 0.44 0.44 (0.33–0.58) 0.43 (0.33–0.56) 
 Adjusted results 13.25 0.04 55 0.50 (0.34–0.74) 0.52 (0.41–0.66) 
H. pylori (the broader definition) 13 16.60 0.17 28 0.56 (0.45–0.69) 0.57 (0.46–0.71) 
CagA-negative strains 1.64 0.80 1.08 (0.76–1.53) 1.07 (0.75–1.52) 
CagA-positive strains** 4.78 0.31 16 0.41 (0.28–0.62) 0.40 (0.28–0.56) 

2Q statistic for homogeneity in random effects model.

P value for the Q statistic in random effects model.

Higgins I2 statistic for heterogeneity in random-effects model.

§Being positive for antibodies against whole-cell or being positive for H. pylori in invasive tests; numbers inside parenthesis refer to number of cases/controls.

Being positive for antibodies against whole-cell or CagA, or positive for H. pylori in invasive tests.

This row compares subjects with CagA-negative strains versus those who are H. pylori negative.

**This row compares subjects with CagA-positive strains versus those who are H. pylori negative.

Begg's funnel plot for the association between H. pylori and EAC is also shown in Fig. 1A. This figure shows the logarithm of the odds ratio (Y axis) versus its SE (X axis). Smaller studies have larger SEs; therefore, points representing these studies are in the right-hand side of the graph. The distribution of the dots on this graph was reasonably symmetric, suggesting no strong evidence for publication bias. Also, there was no evidence for bias using either Begg and Mazumdar's method (P for rank correlation = 0.76) or Egger's weighted regression method (P for bias = 0.71). After excluding small studies, defined as those having a SE >0.5, the summary OR (95% CI) for H. pylori positivity was 0.58 (0.47-0.73).

Table 2 also shows the results of subgroup analyses. Similar to the overall association, every subgroup analysis showed an inverse association between H. pylori positivity and EAC risk. For population-based studies, the OR (95% CI) was 0.58 (0.43-0.76). The ORs (95% CIs) for Western and Eastern studies were 0.57 (0.47-0.70) and 0.32 (0.10-1.02), respectively. Only one study (25) was from an Eastern country. The summary OR (95% CI) for studies that used serologic tests was 0.59 (0.48-0.73). Among the studies that matched for age, the summary OR (95% CI) was 0.58 (0.46-0.75). The summary OR (95% CI) for studies that included Barrett's esophagus in their diagnostic criteria (20, 36, 45, 48, 53) was 0.44 (0.33-0.58). Analysis of adjusted ORs (95% CIs) yielded a summary OR (95% CI) of 0.50 (0.34-0.74). There was no evidence for significant heterogeneity in the subgroup analyses, except for the adjusted analyses, which showed a marginally significant Q statistic (P = 0.04).

When we used the broader definition of H. pylori positivity (being positive for H. pylori or CagA), there was little change in the results, and the overall random-effects OR (95% CI) was 0.56 (0.45-0.69). There was also an inverse association between H. pylori and EAC in all subgroup analyses (results not shown).

Eight of the studies reported on antibodies to CagA, and in five of these, the simultaneous status of IgG antibodies to both CagA and whole-cell antigen was known. In this latter group of studies, the summary ORs (95% CIs) for carrying CagA-negative and CagA-positive H. pylori strains, versus being H. pylori negative, were 1.08 (0.76-1.53) and 0.41 (0.28-0.62), respectively. These two summary ORs were statistically significantly different from each other (P < 0.01). Figure 2A shows the associations between CagA-negative and CagA-positive strains and EAC separately. All five studies show inverse associations for CagA-positive strains, but the results for CagA-negative strains are mixed.

Fig. 2

The association between CagA-positive and CagA-negative strains and esophageal cancer. Studies are sorted in order of publication year. A, esophageal adenocarcinoma. B, esophageal squamous cell carcinoma.

Fig. 2

The association between CagA-positive and CagA-negative strains and esophageal cancer. Studies are sorted in order of publication year. A, esophageal adenocarcinoma. B, esophageal squamous cell carcinoma.

Close modal

Esophageal squamous cell carcinoma

Figure 1B and Table 3 show the results for the association between H. pylori and ESCC. Nine studies, with a total of 921 cases and 2,743 controls, were included in this analysis. As shown in Fig. 1B, the results varied substantially, on both sides of the neutral line, and the ORs (95% CIs) ranged from 0.37 (0.22-0.62) to 2.11 (1.15-3.90), statistically significant in opposite directions. The overall summary ORs (95% CIs) using the random-effects and fixed-effects models were 1.10 (0.78-1.55) and 1.07 (0.91-1.26), respectively. Indices of heterogeneity are shown in Table 3. For the overall analysis, the Q statistic was significant (P < 0.01) and the I2 statistic showed a high variation (73%) among study results.

Table 3

Summary statistics for the association between H. pylori and esophageal squamous cell carcinoma

No. studiesQ statistic*PI2 (%)Random effects OR (95% CI)Fixed effects OR (95% CI)
H. pylori (921/2,743)§       
 All studies 29.76 <0.01 73 1.10 (0.78–1.55) 1.07 (0.91–1.26) 
 Large studies (SE <0.5) 29.76 <0.01 73 1.10 (0.78–1.55) 1.07 (0.91–1.26) 
 Population-based studies 27.52 <0.01 82 1.00 (0.62–1.60) 1.01 (0.84–1.21) 
 Western studies 8.21 0.04 63 1.17 (0.71–1.95) 1.16 (0.87–1.56) 
 Eastern studies 21.17 <0.01 81 1.05 (0.63–1.77) 1.03 (0.85–1.25) 
 Studies used serologic tests 29.76 <0.01 73 1.10 (0.78–1.55) 1.07 (0.91–1.26) 
 Studies with age-matched controls 10.47 0.06 52 1.28 (0.89–1.83) 1.27 (1.00–1.61) 
 Adjusted results 13.54 0.04 56 0.99 (0.67–1.45) 1.04 (0.84–1.29) 
H. pylori (the broader definition) 30.66 <0.01 74 1.26 (0.88–1.80) 1.20 (1.01–1.42) 
CagA-negative strains 2.77 0.43 1.41 (1.00–1.97) 1.37 (0.98–1.90) 
CagA-positive strains** 2.60 0.46 1.01 (0.80–1.27) 1.01 (0.80–1.27) 
No. studiesQ statistic*PI2 (%)Random effects OR (95% CI)Fixed effects OR (95% CI)
H. pylori (921/2,743)§       
 All studies 29.76 <0.01 73 1.10 (0.78–1.55) 1.07 (0.91–1.26) 
 Large studies (SE <0.5) 29.76 <0.01 73 1.10 (0.78–1.55) 1.07 (0.91–1.26) 
 Population-based studies 27.52 <0.01 82 1.00 (0.62–1.60) 1.01 (0.84–1.21) 
 Western studies 8.21 0.04 63 1.17 (0.71–1.95) 1.16 (0.87–1.56) 
 Eastern studies 21.17 <0.01 81 1.05 (0.63–1.77) 1.03 (0.85–1.25) 
 Studies used serologic tests 29.76 <0.01 73 1.10 (0.78–1.55) 1.07 (0.91–1.26) 
 Studies with age-matched controls 10.47 0.06 52 1.28 (0.89–1.83) 1.27 (1.00–1.61) 
 Adjusted results 13.54 0.04 56 0.99 (0.67–1.45) 1.04 (0.84–1.29) 
H. pylori (the broader definition) 30.66 <0.01 74 1.26 (0.88–1.80) 1.20 (1.01–1.42) 
CagA-negative strains 2.77 0.43 1.41 (1.00–1.97) 1.37 (0.98–1.90) 
CagA-positive strains** 2.60 0.46 1.01 (0.80–1.27) 1.01 (0.80–1.27) 

2Q statistic for homogeneity in the random-effects model.

P value for the Q statistic in the random-effects model.

Higgins I2 statistic for heterogeneity in the random-effects model.

§Being positive for antibodies against whole cell or being positive for H. pylori in invasive tests; numbers inside parenthesis refer to number of cases/controls.

Being positive for antibodies against whole cell or CagA, or positive for H. pylori in invasive tests.

This row compares subjects with CagA-negative strains versus those who are H. pylori negative.

**This row compares subjects with CagA-positive strains versus those who are H. pylori negative.

Begg's funnel plot for the association between H. pylori and ESCC is shown in Fig. 1B. The distribution of the dots around the summary line was symmetric, and there was no evidence of bias using either Begg's method (P = 0.47) or Egger's method (P for bias = 0.84). All studies had a SE of <0.5.

Subgroup analysis results are shown in Table 3. The summary OR (95% CI) for population-based studies was 1.00 (0.62-1.60). The ORs (95% CIs) for Western and Eastern studies were 1.17 (0.71-1.95) and 1.05 (0.63-1.77), respectively. The OR (95% CI) for studies that used serologic tests was 1.10 (0.78-1.55). The summary OR (95% CI) for studies that matched for age was 1.28 (0.89-1.83). When the adjusted ORs were analyzed, the overall OR (95% CI) was 0.99 (0.67-1.45). Similar to the overall analysis, the I2 and Q statistics suggested high and statistically significant heterogeneity in the subgroup analyses.

When the broader definition of H. pylori positivity was used, the random-effects OR for the overall association changed only slightly and remained nonsignificant. However, when studies were classified by geographic region, there was a statistically significant association between H. pylori and ESCC in Western studies, with an OR (95% CI) of 1.65 (1.17-2.32). Other subgroup analyses yielded results that were qualitatively similar to those found with the earlier definition of H. pylori positivity (results not shown).

Four studies reported on CagA results, and in all of them the simultaneous status of antibodies to CagA and whole-cell were known. Two of these studies dominated the results (Fig. 2B). The summary ORs (95% CIs) for carrying CagA-negative and CagA-positive strains, versus being H. pylori–negative, were 1.41 (1.00-1.97) and 1.01 (0.80-1.27), respectively. These two summary OR point estimates were not statistically significantly different from each other.

The results of this meta-analysis suggest that colonization of the stomach with CagA-positive strains of H. pylori may protect against EAC.

H. pylori has coexisted with modern humans since their origin (60), and once it could be found in the stomachs of most humans. With advances in sanitation and use of antibiotics, however, this bacterium is rapidly disappearing from human populations (61), especially in Western countries. In the United States, for example, data from the third National Health and Nutritional Examination Survey (1988-1991) showed that serum samples from 57% of the population older than 70 years of age, versus 17% of the population between 20 and 29 years of age, were positive for IgG antibodies against H. pylori (62). More recent data from the National Health and Nutritional Examination Survey 1999-2000 show a positive IgG seroprevalence of only 5% in children younger than 10 years old who were born in the 1990s (63). Given that H. pylori colonization in most people occurs before the age of 10 years (64), these numbers show a substantial decline in H. pylori in a period of 70 years. This decrease mostly reflects a cohort effect (65) rather than eradication of H. pylori in individuals over time.

With changes in the prevalence of H. pylori, incidence rates of diseases caused, or prevented, by this organism change. H. pylori is a known cause of noncardia gastric cancer (66). Incidence rates of this cancer have been sharply declining in most parts of the world in the past few decades (7). In contrast, rates of EAC have steeply increased in Western countries during this same period (13, 67). Once a rare cancer, EAC now constitutes approximately half of all esophageal cancer cases in some Western populations (1113). Our results suggest that CagA-positive strains of H. pylori, which constitute the majority of H. pylori strains, may protect against EAC, and that increasing EAC rates may be partly due to the decline of H. pylori in human populations. In parallel with EAC rates, the incidence rates of gastric cardia adenocarcinoma, another cancer inversely associated with H. pylori prevalence (68), are increasing in some Western countries (67). However, it is unclear whether this latter inverse association is real or it merely reflects misclassification of EAC for gastric cardia adenocarcinoma (33, 69). Another observation consistent with the hypothesis that H. pylori disappearance is contributing to the increased EAC rates is that EAC rates are still low in most developing countries (9, 10), where H. pylori is still common.

H. pylori may decrease risk of EAC by reducing acid production in the stomach and hence reducing acid reflux to the esophagus (19). It may also reduce EAC risk by decreasing the production of the hormone ghrelin, which is mostly secreted from the stomach and stimulates appetite (70). A reduction in the level of ghrelin may lead to lower rates of obesity, an important risk factor for EAC (71).

The protective association of H. pylori with EAC or gastric cardia adenocarcinoma may be part of a broader phenomenon. The long history of coexistence of this organism with humans, despite its disease-causing potential, may suggest that H. pylori also has some beneficial effects to humans (61), including possible roles in reducing diarrheal diseases and asthma (63, 72, 73). Therefore, in this article, we have used the term H. pylori “colonization,” rather than “infection,” to describe the presence of H. pylori living in the stomach. The reciprocal link of H. pylori with both EAC and asthma may be due to lower acid reflux, which is a risk factor for both diseases, or it could be due to modulation of the hormones leptin and ghrelin, which have immunoregulatory effects (reviewed in refs. 72, 74).

The decline of H. pylori colonization can only partly explain the sharp increase in EAC incidence rates. With an OR of 0.5, even if H. pylori entirely disappeared, EAC incidence could increase at most by 2-fold; thus, part of the nearly 4-fold increased incidence observed in some populations (67) must be due to other reasons. Recent epidemiologic studies have found three important risk factors for EAC, namely gastroesophageal reflux, obesity, and smoking (14, 15, 71, 75). Whether, and how much, a change in the prevalence of these factors has contributed to the surge of EAC cases in the past few decades is still debated.

We conducted several analyses to examine the robustness of the association between H. pylori and EAC. The point estimate of the OR for each individual study in the meta-analysis was lower than 1, and there was little heterogeneity among these studies. Subgroup analyses also showed remarkably consistent ORs. When data analysis was limited to population-based studies, to studies from Western or Eastern countries, to studies that used serologic tests to determine exposure, to studies that matched for age, to larger studies, or to studies that included Barrett's esophagus in their diagnostic criteria, the summary OR remained lower than 0.60. When we used adjusted estimates, the summary OR was 0.50. Therefore, the results were quite robust. Likewise, using the broader definition of H. pylori positivity had very little or no impact on the results. We did not find any evidence for publication bias by using funnel plots or formal statistical tests.

CagA-positive strains of H. pylori have been disappearing faster than the CagA-negative ones (76). Interestingly, the inverse association between H. pylori and EAC was seen only with CagA-positive strains. Forest plots showed that this pattern was consistent across studies. It should be noted, however, that only 5 of the 13 selected studies could be used for comparing the effects of CagA-positive and CagA-negative strains. Therefore, more studies may still be needed to confirm this pattern. As discussed earlier, CagA-positive strains confer higher risk of noncardia gastric cancer than CagA-negative strains (18). Therefore, CagA-positive strains may also have stronger associations with other diseases that are caused, or prevented, by H. pylori. CagA protein can be delivered into gastric epithelial cells, and it may increase the risk of gastric cancer by increasing the turnover of the gastric epithelium (17). CagA-positive strains are also more likely to have the s1 allele of vacA, which encodes a molecule that affects epithelial cells (77) and may increase gastric cancer risk (78), and are also more likely to express the babA product, which controls adherence of H. pylori organisms to Lewisb antigens on gastric epithelial cells (77). The biological reasons for the inverse association between CagA-positive H. pylori and EAC need to be further investigated.

We found no overall association between H. pylori and ESCC risk. However, the point estimates differed substantially and qualitatively among studies, resulting in large heterogeneity indices. Limiting studies to population-based studies, studies from Western or Eastern countries, studies that used serologic tests, studies that matched for age, or studies using adjusted results made little change in summary estimates and did not reduce heterogeneity. Therefore, the source of the observed heterogeneity is unclear. Gastric colonization with CagA-positive strains was not associated with ESCC risk. Compared with H. pylori–negative subjects, CagA-negative strains were associated with a marginally significant increased risk of ESCC. However, the bulk of the data for the latter analysis came from only two studies, and further studies are needed to make more definitive conclusions. An association was observed in studies from Western countries when we used the broader definition of H. pylori positivity. Again, there were only four studies in this analysis, and further data are needed to have more confidence in the results.

One other meta-analysis has previously examined the association between H. pylori and esophageal cancer (79). Our meta-analysis differs from this previous evaluation in several respects. One difference is the choice of published articles. The two meta-analyses share only six articles that examined the association between H. pylori and EAC, and only four articles that examined the association between H. pylori and ESCC. We excluded several of the publications used in the previous meta-analysis because they included duplicate data from the same study; we substituted newer papers from some studies; and we included several additional recent studies. We also conducted multiple subgroup analyses to examine the robustness of our data to the choice of study methods and other factors. We also examined the effects of CagA-positive and CagA-negative strains of H. pylori separately versus H. pylori–negative subjects, rather than comparing CagA-positive subjects versus all other subjects. Despite these differences, both meta-analyses found that H. pylori protects against EAC and is not significantly related to ESCC risk. Also, both meta-analyses found that the association of H. pylori with EAC was largely homogeneous across studies, but there was substantial and statistically significant heterogeneity in results with respect to ESCC.

The strengths of this meta-analysis include the evaluation of 19 published studies with a large number of cases and controls, presenting multiple subgroup analyses, and using several methods to examine study heterogeneity and publication bias. This meta-analysis also has limitations. Combining observational studies conducted in different populations with various qualities of design to obtain summary ORs and 95% CIs can sometimes be misleading (80) and summary statistics need to be interpreted with caution (81). However, as mentioned above, at least for EAC, there was little evidence of heterogeneity and the results were robust to multiple subgroup analyses.

In conclusion, we found an inverse association between CagA-positive strains of H. pylori and risk of esophageal adenocarcinoma. The prominent decline of H. pylori colonization, especially CagA-positive strains, may be responsible for part of the recent increase in esophageal adenocarcinoma rates in Western countries.

No potential conflicts of interest were disclosed.

We thank Dr. Sanford M. Dawsey for reviewing the manuscript and giving us his invaluable comments.

1
Marshall
BJ
,
Warren
JR
. 
Unidentified curved bacilli in the stomach of patients with gastritis and peptic ulceration
.
Lancet
1984
;
1
:
1311
5
.
2
Suerbaum
S
,
Michetti
P
. 
Helicobacter pylori infection
.
N Engl J Med
2002
;
347
:
1175
86
.
3
Raderer
M
,
Wrba
F
,
Kornek
G
, et al
. 
Association between Helicobacter pylori infection and pancreatic cancer
.
Oncology
1998
;
55
:
16
9
.
4
Stolzenberg-Solomon
RZ
,
Blaser
MJ
,
Limburg
PJ
, et al
. 
Helicobacter pylori seropositivity as a risk factor for pancreatic cancer
.
J Natl Cancer Inst
2001
;
93
:
937
41
.
5
Limburg
PJ
,
Stolzenberg-Solomon
RZ
,
Colbert
LH
, et al
. 
Helicobacter pylori seropositivity and colorectal cancer risk: a prospective study of male smokers
.
Cancer Epidemiol Biomarkers Prev
2002
;
11
:
1095
9
.
6
Shmuely
H
,
Passaro
D
,
Figer
A
, et al
. 
Relationship between Helicobacter pylori CagA status and colorectal cancer
.
Am J Gastroenterol
2001
;
96
:
3406
10
.
7
Kamangar
F
,
Dores
GM
,
Anderson
WF
. 
Patterns of cancer incidence, mortality, and prevalence across five continents: defining priorities to reduce cancer disparities in different geographic regions of the world
.
J Clin Oncol
2006
;
24
:
2137
50
.
8
Corley
DA
,
Buffler
PA
. 
Oesophageal and gastric cardia adenocarcinomas: analysis of regional variation using the Cancer Incidence in Five Continents database
.
Int J Epidemiol
2001
;
30
:
1415
25
.
9
Tran
GD
,
Sun
XD
,
Abnet
CC
, et al
. 
Prospective study of risk factors for esophageal and gastric cancers in the Linxian general population trial cohort in China
.
Int J Cancer
2005
;
113
:
456
63
.
10
Islami
F
,
Kamangar
F
,
Aghcheli
K
, et al
. 
Epidemiologic features of upper gastrointestinal tract cancer in northeastern Iran
.
Br J Cancer
2004
;
90
:
1402
6
.
11
Brown
LM
,
Devesa
SS
. 
Epidemiologic trends in esophageal and gastric cancer in the United States
.
Surg Oncol Clin N Am
2002
;
11
:
235
56
.
12
Freedman
ND
,
Abnet
CC
,
Leitzmann
MF
, et al
. 
A prospective study of tobacco, alcohol, and the risk of esophageal and gastric cancer subtypes
.
Am J Epidemiol
2007
;
165
:
1424
33
.
13
Powell
J
,
McConkey
CC
,
Gillison
EW
,
Spychal
RT
. 
Continuing rising trend in oesophageal adenocarcinoma
.
Int J Cancer
2002
;
102
:
422
7
.
14
Gammon
MD
,
Schoenberg
JB
,
Ahsan
H
, et al
. 
Tobacco, alcohol, and socioeconomic status and adenocarcinomas of the esophagus and gastric cardia
.
J Natl Cancer Inst
1997
;
89
:
1277
84
.
15
Vaughan
TL
,
Davis
S
,
Kristal
A
,
Thomas
DB
. 
Obesity, alcohol, and tobacco as risk factors for cancers of the esophagus and gastric cardia: adenocarcinoma versus squamous cell carcinoma
.
Cancer Epidemiol Biomarkers Prev
1995
;
4
:
85
92
.
16
Bickston
SJ
,
Peura
DA
Diagnostic tests for Helicobacter pylori infection
. . Last accessed: March 10, 2008.
17
Hatakeyama
M
. 
Oncogenic mechanisms of the Helicobacter pylori CagA protein
.
Nat Rev Cancer
2004
;
4
:
688
94
.
18
Huang
JQ
,
Zheng
GF
,
Sumanac
K
,
Irvine
EJ
,
Hunt
RH
. 
Meta-analysis of the relationship between cagA seropositivity and gastric cancer
.
Gastroenterology
2003
;
125
:
1636
44
.
19
Chow
WH
,
Blaser
MJ
,
Blot
WJ
, et al
. 
An inverse relation between cagA+ strains of Helicobacter pylori infection and risk of esophageal and gastric cardia adenocarcinoma
.
Cancer Res
1998
;
58
:
588
90
.
20
Anandasabapathy
S
,
Jhamb
J
,
Davila
M
,
Wei
C
,
Morris
J
,
Bresalier
R
. 
Clinical and endoscopic factors predict higher pathologic grades of Barrett dysplasia
.
Cancer
2007
;
109
:
668
74
.
21
Anderson
LA
,
Murphy
SJ
,
Johnston
BT
, et al
. 
Relationship between Helicobacter pylori infection and gastric atrophy and the stages of the oesophageal inflammation, metaplasia, adenocarcinoma sequence: results from the FINBAR case-control study
.
Gut
2008
;
57
:
734
9
.
22
Cameron
AJ
,
Souto
EO
,
Smyrk
TC
. 
Small adenocarcinomas of the esophagogastric junction: association with intestinal metaplasia and dysplasia
.
Am J Gastroenterol
2002
;
97
:
1375
80
.
23
de Martel
C
,
Llosa
AE
,
Farr
SM
, et al
. 
Helicobacter pylori infection and the risk of development of esophageal adenocarcinoma
.
J Infect Dis
2005
;
191
:
761
7
.
24
de Martel
C
,
Haggerty
TD
,
Corley
DA
,
Vogelman
JH
,
Orentreich
N
,
Parsonnet
J
. 
Serum ghrelin levels and risk of subsequent adenocarcinoma of the esophagus
.
Am J Gastroenterol
2007
;
102
:
1166
72
.
25
Derakhshan
MH
,
Malekzadeh
R
,
Watabe
H
, et al
. 
Combination of gastric atrophy, reflux symptoms and histological subtype indicates two distinct aetiologies of gastric cardia cancer
.
Gut
2007
;
57
:
298
305
.
26
Driessen
A
,
Van Raemdonck
D
,
De Leyn
P
, et al
. 
Are carcinomas of the cardia oesophageal or gastric adenocarcinomas?
Eur J Cancer
2003
;
39
:
2487
94
.
27
El Omar
EM
,
Rabkin
CS
,
Gammon
MD
, et al
. 
Increased risk of noncardia gastric cancer associated with proinflammatory cytokine gene polymorphisms
.
Gastroenterology
2003
;
124
:
1193
201
.
28
Fruh
M
,
Zhou
W
,
Zhai
R
, et al
. 
Polymorphisms of inflammatory and metalloproteinase genes, Helicobacter pylori infection and the risk of oesophageal adenocarcinoma
.
Br J Cancer
2008
;
98
:
689
92
.
29
Grimley
CE
,
Holder
RL
,
Loft
DE
,
Morris
A
,
Nwokolo
CU
. 
Helicobacter pylori-associated antibodies in patients with duodenal ulcer, gastric and oesophageal adenocarcinoma
.
Eur J Gastroenterol Hepatol
1999
;
11
:
503
9
.
30
Henihan
RD
,
Stuart
RC
,
Nolan
N
,
Gorey
TF
,
Hennessy
TP
,
O'Morain
CA
. 
Barrett's esophagus and the presence of Helicobacter pylori
.
Am J Gastroenterol
1998
;
93
:
542
6
.
31
Iijima
K
,
Koike
T
,
Abe
Y
, et al
. 
Extensive gastric atrophy: an increased risk factor for superficial esophageal squamous cell carcinoma in Japan
.
Am J Gastroenterol
2007
;
102
:
1603
9
.
32
Jansson
C
,
Johansson
AL
,
Nyren
O
,
Lagergren
J
. 
Socioeconomic factors and risk of esophageal adenocarcinoma: a nationwide Swedish case-control study
.
Cancer Epidemiol Biomarkers Prev
2005
;
14
:
1754
61
.
33
Kamangar
F
,
Qiao
YL
,
Blaser
MJ
, et al
. 
Helicobacter pylori and oesophageal and gastric cancers in a prospective study in China
.
Br J Cancer
2007
;
96
:
172
6
.
34
Lord
RV
,
Frommer
DJ
,
Inder
S
,
Tran
D
,
Ward
RL
. 
Prevalence of Helicobacter pylori infection in 160 patients with Barrett's oesophagus or Barrett's adenocarcinoma
.
Aust N Z J Surg
2000
;
70
:
26
33
.
35
Oberg
S
,
Peters
JH
,
Nigro
JJ
, et al
. 
Helicobacter pylori is not associated with the manifestations of gastroesophageal reflux disease
.
Arch Surg
1999
;
134
:
722
6
.
36
Peek
RM
 Jr.
,
Vaezi
MF
,
Falk
GW
, et al
. 
Role of Helicobacter pylori cagA(+) strains and specific host immune responses on the development of premalignant and malignant lesions in the gastric cardia
.
Int J Cancer
1999
;
82
:
520
4
.
37
Quddus
MR
,
Henley
JD
,
Sulaiman
RA
,
Palumbo
TC
,
Gnepp
DR
. 
Helicobacter pylori infection and adenocarcinoma arising in Barrett's esophagus
.
Hum Pathol
1997
;
28
:
1007
9
.
38
Robeycafferty
SS
,
Ro
JY
,
Cleary
KR
. 
The prevalence of Campylobacter pylori in gastric biopsies from cancer-patients
.
Mod Pathol
1989
;
2
:
473
6
.
39
Ruol
A
,
Parenti
A
,
Zaninotto
G
, et al
. 
Intestinal metaplasia is the probable common precursor of adenocarcinoma in Barrett esophagus and adenocarcinoma of the gastric cardia
.
Cancer
2000
;
88
:
2520
8
.
40
Siman
JH
,
Forsgren
A
,
Berglund
G
,
Floren
CH
. 
Helicobacter pylori infection is associated with a decreased risk of developing oesophageal neoplasms
.
Helicobacter
2001
;
6
:
310
6
.
41
Siman
JH
,
Engstrand
L
,
Berglund
G
,
Forsgren
A
,
Floren
CH
. 
Helicobacter pylori and CagA seropositivity and its association with gastric and oesophageal carcinoma
.
Scand J Gastroenterol
2007
;
42
:
933
40
.
42
Talley
NJ
,
Zinsmeister
AR
,
Weaver
A
, et al
. 
Gastric adenocarcinoma and Helicobacter pylori infection
.
J Natl Cancer Inst
1991
;
83
:
1734
9
.
43
Torrado
J
,
Ruiz
B
,
Garay
J
, et al
. 
Blood-group phenotypes, sulfomucins, and Helicobacter pylori in Barrett's esophagus
.
Am J Surg Pathol
1997
;
21
:
1023
9
.
44
Vicari
JJ
,
Peek
RM
,
Falk
GW
, et al
. 
The seroprevalence of cagA-positive Helicobacter pylori strains in the spectrum of gastroesophageal reflux disease
.
Gastroenterology
1998
;
115
:
50
7
.
45
Vieth
M
,
Masoud
B
,
Meining
A
,
Stolte
M
. 
Helicobacter pylori infection: protection against Barrett's mucosa and neoplasia?
.
Digestion
2000
;
62
:
225
31
.
46
Wang
KX
,
Wang
XF
,
Peng
JL
,
Cui
YB
,
Wang
J
,
Li
CP
. 
Detection of serum anti-Helicobacter pylori immunoglobulin G in patients with different digestive malignant tumors
.
World J Gastroenterol
2003
;
9
:
2501
4
.
47
Wang
Z
,
Tang
L
,
Sun
G
, et al
. 
Etiological study of esophageal squamous cell carcinoma in an endemic region: a population-based case control study in Huaian, China
.
BMC Cancer
2006
;
6
:
287
.
48
Weston
AP
,
Badr
AS
,
Topalovski
M
,
Cherian
R
,
Dixon
A
,
Hassanein
RS
. 
Prospective evaluation of the prevalence of gastric Helicobacter pylori infection in patients with GERD, Barrett's esophagus, Barrett's dysplasia, and Barrett's adenocarcinoma
.
Am J Gastroenterol
2000
;
95
:
387
94
.
49
Wright
TA
,
Myskow
M
,
Kingsnorth
AN
. 
Helicobacter pylori colonization of Barrett's esophagus and its progression to cancer
.
Dis Esophagus
1997
;
10
:
196
200
.
50
Wu
AH
,
Crabtree
JE
,
Bernstein
L
, et al
. 
Role of Helicobacter pylori CagA+ strains and risk of adenocarcinoma of the stomach and esophagus
.
Int J Cancer
2003
;
103
:
815
21
.
51
Wu
AH
,
Tseng
CC
,
Hankin
J
,
Bernstein
L
. 
Fiber intake and risk of adenocarcinomas of the esophagus and stomach
.
Cancer Causes Control
2007
;
18
:
713
22
.
52
Wu
DC
,
Wu
IC
,
Lee
JM
, et al
. 
Helicobacter pylori infection: a protective factor for esophageal squamous cell carcinoma in a Taiwanese population
.
Am J Gastroenterol
2005
;
100
:
588
93
.
53
Ye
W
,
Held
M
,
Lagergren
J
, et al
. 
Helicobacter pylori infection and gastric atrophy: risk of adenocarcinoma and squamous-cell carcinoma of the esophagus and adenocarcinoma of the gastric cardia
.
J Natl Cancer Inst
2004
;
96
:
388
96
.
54
Romero-Gallo
J
,
Perez-Perez
GI
,
Novick
RP
,
Kamath
P
,
Norbu
T
,
Blaser
MJ
. 
Responses of endoscopy patients in Ladakh, India, to Helicobacter pylori whole-cell and Cag A antigens
.
Clin Diagn Lab Immunol
2002
;
9
:
1313
7
.
55
Moayyedi
P
. 
Meta-analysis: can we mix apples and oranges?
.
Am J Gastroenterol
2004
;
99
:
2297
301
.
56
Sterne
JA
,
Egger
M
,
Davey Smith
G
. 
Systematic reviews in health care: Investigating and dealing with publication and other biases in meta-analysis
.
BMJ
2001
;
323
:
101
5
.
57
Begg
CB
,
Mazumdar
M
. 
Operating characteristics of a rank correlation test for publication bias
.
Biometrics
1994
;
50
:
1088
101
.
58
Egger
M
,
Davey Smith
G
,
Schneider
M
,
Minder
C
. 
Bias in meta-analysis detected by a simple, graphical test
.
BMJ
1997
;
315
:
629
34
.
59
Higgins
JP
,
Thompson
SG
,
Deeks
JJ
,
Altman
DG
. 
Measuring inconsistency in meta-analyses
.
BMJ
2003
;
327
:
557
60
.
60
Falush
D
,
Wirth
T
,
Linz
B
, et al
. 
Traces of human migrations in Helicobacter pylori populations
.
Science
2003
;
299
:
1582
5
.
61
Blaser
MJ
. 
Who are we? Indigenous microbes and the ecology of human diseases
.
EMBO Rep
2006
;
7
:
956
60
.
62
Everhart
JE
,
Kruszon-Moran
D
,
Perez-Perez
GI
,
Tralka
TS
,
McQuillan
G
. 
Seroprevalence and ethnic differences in Helicobacter pylori infection among adults in the United States
.
J Infect Dis
2000
;
181
:
1359
63
.
63
Chen
Y
,
Blaser
MJ
. 
Helicobacter pylori colonization is inversely associated with childhood asthma
.
J Infect Dis
2008
;
198
:
553
60
.
64
Malaty
HM
,
El-Kasabany
A
,
Graham
DY
, et al
. 
Age at acquisition of Helicobacter pylori infection: a follow-up study from infancy to adulthood
.
Lancet
2002
;
359
:
931
5
.
65
Banatvala
N
,
Mayo
K
,
Megraud
F
,
Jennings
R
,
Deeks
JJ
,
Feldman
RA
. 
The cohort effect and Helicobacter pylori
.
J Infect Dis
1993
;
168
:
219
21
.
66
Helicobacter and Cancer Collaborative Group
. 
Gastric cancer and Helicobacter pylori: a combined analysis of 12 case control studies nested within prospective cohorts
.
Gut
2001
;
49
:
347
53
.
67
Devesa
SS
,
Blot
WJ
,
Fraumeni
JF
 Jr
. 
Changing patterns in the incidence of esophageal and gastric carcinoma in the United States
.
Cancer
1998
;
83
:
2049
53
.
68
Kamangar
F
,
Dawsey
SM
,
Blaser
MJ
, et al
. 
Opposing risks of gastric cardia and noncardia gastric adenocarcinomas associated with Helicobacter pylori seropositivity
.
J Natl Cancer Inst
2006
;
98
:
1445
52
.
69
Dawsey
SM
,
Mark
SD
,
Taylor
PR
,
Limburg
PJ
. 
Gastric cancer and H. pylori
.
Gut
2002
;
51
:
457
8
.
70
Wren
AM
,
Bloom
SR
. 
Gut hormones and appetite control
.
Gastroenterology
2007
;
132
:
2116
30
.
71
Whiteman
DC
,
Sadeghi
S
,
Pandeya
N
, et al
. 
Combined effects of obesity, acid reflux and smoking on the risk of adenocarcinomas of the oesophagus
.
Gut
2007
;
57
:
173
80
.
72
Blaser
MJ
,
Chen
Y
,
Reibman
J
. 
Does Helicobacter pylori protect against asthma and allergy?
Gut
2008
;
57
:
561
7
.
73
Chen
Y
,
Blaser
MJ
. 
Inverse associations of Helicobacter pylori with asthma and allergy
.
Arch Intern Med
2007
;
167
:
821
7
.
74
Blaser
MJ
. 
An endangered species in the stomach
.
Sci Am
2005
;
292
:
38
45
.
75
Lagergren
J
,
Bergstrom
R
,
Lindgren
A
,
Nyren
O
. 
Symptomatic gastroesophageal reflux as a risk factor for esophageal adenocarcinoma
.
N Engl J Med
1999
;
340
:
825
31
.
76
Perez-Perez
GI
,
Salomaa
A
,
Kosunen
TU
, et al
. 
Evidence that cagA(+) Helicobacter pylori strains are disappearing more rapidly than cagA(−) strains
.
Gut
2002
;
50
:
295
8
.
77
Blaser
MJ
,
Berg
DE
. 
Helicobacter pylori genetic diversity and risk of human disease
.
J Clin Invest
2001
;
107
:
767
73
.
78
Figueiredo
C
,
Machado
JC
,
Pharoah
P
, et al
. 
Helicobacter pylori and interleukin 1 genotyping: an opportunity to identify high-risk individuals for gastric carcinoma
.
J Natl Cancer Inst
2002
;
94
:
1680
7
.
79
Rokkas
T
,
Pistiolas
D
,
Sechopoulos
P
,
Robotis
I
,
Margantinis
G
. 
Relationship between Helicobacter pylori infection and esophageal neoplasia: a meta-analysis
.
Clin Gastroenterol Hepatol
2007
;
5
:
1413
7
.
80
Shapiro
S
. 
Meta-analysis/Sh meta-analysis
.
Am J Epidemiol
1994
;
140
:
771
8
.
81
Egger
M
,
Schneider
M
,
Davey Smith
G
. 
Spurious precision? Meta-analysis of observational studies
.
BMJ
1998
;
316
:
140
4
.

Supplementary data